可溶性白细胞介素-6受体介导的疲乏突显接受放疗的早期乳腺癌患者免疫异质性
这项前瞻性队列研究纳入100例0-IIIa期乳腺癌女性,接受40 Gy/15次辅助放疗,分析局部乳腺照射剂量体积参数与血清sIL-6R、白细胞计数及疲乏的关联。结果显示照射总体积超过2040 cm³(50%等剂量线内)者sIL-6R显著升高,疲乏组在放疗期间sIL-6R均值显著高于非疲乏组,提示局部照射诱导的全身sIL-6R升高与疲乏相关并反映固有免疫差异。
要点
- 50%等剂量线内照射总体积>2040 cm³者sIL-6R显著更高(P=.003),控制BMI后仅治疗后显著。
- 38%患者归类为疲乏,放疗第15次后sIL-6R均值47.6 ng/dL vs 非疲乏组41.6 ng/dL(P=.01)。
- 疲乏组白细胞及亚群计数较非疲乏组低4%-9%,但差异无统计学意义。
核心结论
- 局部照射在治疗期间诱导报告疲乏水平升高的患者全身sIL-6R增加,该行为反应似乎反映固有宿主免疫变异,进而介导放疗的细胞和/或心理应激。
研究设计与样本
- 前瞻性队列研究,招募100例0-IIIa期乳腺癌女性,接受40 Gy/15次/3周辅助放疗,无既往或同期化疗。
- 从治疗计划获取剂量体积参数,在基线、10次和15次后及放疗后4周检测血清sIL-6R、白细胞计数和自报疲乏。
主要发现
- 50%等剂量线内照射总体积>2040 cm³者sIL-6R浓度显著更高(P=.003),控制体重指数后仅治疗后仍显著。
- 10%等剂量线内肝脏照射体积与放疗期间及之后sIL-6R浓度相关(ρ=.3-.4;P=.03-.007)。
- 38%队列归类为疲乏,疲乏组所有观察点sIL-6R均值更高,仅放疗期间差异有统计学意义:15次后疲乏组均值47.6 ng/dL(SD 11.2)vs 非疲乏组41.6 ng/dL(SD 11.4)(P=.01)。
- 队列白细胞计数及亚群自基线持续下降,疲乏组较非疲乏组基线低4%、治疗期间及之后低7%-9%,但差异无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to explore the associations between dose-volume parameters of localized breast irradiation, longitudinal interleukin-6 soluble receptor (sIL-6R), and leukocyte counts as markers of an immune-mediated response and fatigue as a centrally-driven behavior. METHODS AND MATERIALS: This prospective cohort study recruited 100 women who were diagnosed with stage 0-IIIa breast cancer, prescribed 40 Gy in 15 fractions over 3 weeks adjuvant radiation therapy, and had no prior or concurrent chemotherapy. Dose-volume parameters were derived from treatment plans and related to serum sIL-6R concentrations, leukocyte counts, and a validated measure of self-reported fatigue at baseline, after 10 and 15 fractions, and 4 weeks after radiation therapy. RESULTS: sIL-6R concertation was significantly higher in patients with a total volume of tissue irradiated within the 50% isodose >2040 cm3 (P = .003). When controlling for body mass index, this result only remained significant after treatment. The volume of liver irradiated within the 10% isodose correlated with the sIL-6R concentration during and after radiation therapy (ρ = .3-.4; P = .03-.007). The 38% of the cohort that was classified as fatigued had a higher mean sIL-6sR concentration at all observation points, but the differences were only statistically significant during radiation therapy: Mean (standard deviation [SD]) after 15 fractions for fatigued patients was 47.6 ng/dL (11.2 SD) versus 41.6 ng/dL (11.4 SD) for nonfatigued patients (P = .01). Cohort leukocyte counts and leukocyte subsets decreased consistently from baseline and the values for the fatigued group were 4% lower at baseline and between 7% and 9% lower during and after treatment compared with those of the nonfatigued group but the differences were not statistically significant. CONCLUSIONS: This is the first study to show that localized irradiation induces increased systemic sIL-6R during treatment in participants who reported elevated levels of fatigue before, during, and after treatment. This behavioral response appears to reflect a variation in innate host immunity, which then mediates the cellular and/or psychological stress of radiation therapy.
引用
- Courtier N, Gambling T, Barrett-Lee P, et al. Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy. Adv Radiat Oncol. 2018. PMID: 30370355. doi:10.1016/j.adro.2018.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。